A retrospective analysis of more than 600,000 U.S. patient records found that adults with type 2 diabetes who escalated their semaglutide dose showed a 6 percent lower risk of major cardiovascular events than similar patients who switched to tirzepatide, a finding presented at Europe's largest diabetes meeting.
What Happened
The analysis examined 636,525 adults with type 2 diabetes on once-weekly semaglutide 1 mg. Within a year, most stayed put, but hundreds of thousands escalated to the 2 mg strength while a smaller group switched to tirzepatide. At follow-up, patients who had escalated showed a statistically significant 6 percent lower risk of major adverse cardiovascular events — the composite of all-cause death, heart attack, and stroke — than those who switched, with the gap holding in a lab-linked subgroup analysis.
The data were drawn from a large U.S. healthcare claims database covering January 2018 through September 2025 and presented at the European Association for the Study of Diabetes annual meeting.
Timeline
- June 2026 — Earlier treatment-pattern findings from the same research program presented at the American Diabetes Association sessions
- September 29, 2026 — Cardiovascular outcomes presented at the EASD annual meeting in Milan
- Study window — Claims data from January 2018 to September 2025, follow-up extending to 720 days
Who Is Affected
- Type 2 diabetes patients on semaglutide whose glycemic control is slipping and face the intensify-or-switch decision
- Prescribers weighing cardiovascular history when choosing between escalating within one drug class and crossing to another
- Both manufacturers — the analysis was funded by semaglutide's maker, which competitors will note
- Payers — treatment intensification patterns shape formulary decisions across millions of patients
What This Means for Researchers
- Association, not causation. This is retrospective claims research: patients were not randomized, and confounding by indication cannot be excluded
- Sponsorship matters. The manufacturer of the favored drug commissioned the analysis; independent replication is essential before the result changes practice
- Channeling is the obvious bias. Patients switched to tirzepatide may differ systematically from those escalated, in ways claims data cannot fully adjust for
- Safety was not assessed. The analysis reports cardiovascular outcomes only; tolerability differences between strategies are outside its scope
- The headline number is modest. A 6 percent relative difference in a composite endpoint is a signal for hypothesis generation, not a treatment mandate
How to Verify Your Peptides
- Both medicines in this study are approved and pharmacy-dispensed, but gray-market copies of both circulate online; see our tirzepatide testing guide and semaglutide testing guide
- Start with how third-party peptide testing works
Safe Alternatives
- Read our semaglutide and tirzepatide research profiles for the published human data
- Compare sources in our vetted vendor directory
Sources
Research presented at the European Association for the Study of Diabetes annual meeting, September 2026; regulatory announcements; industry reports.